Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed · Phase 2

Conditions studied: Attention-Deficit/Hyperactivity Disorder

In brief

The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

Key facts

Study ID

NCT00686933

Run by

AbbVie (prior sponsor, Abbott)

People needed

117

Starts

2008-05-01

Expected to finish

2008-10-01

Last updated by the study team

2013-01-21

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject was randomized into Study M10-346 and completed the study.
• Female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements.
• Male subjects must agree to comply with applicable contraceptive requirements.
• The subject is judged to be in generally good health.

You may not qualify if…

• The subject has taken any ADHD medication between the last dose of study drug in Study M10-346 and the first dose of study drug in the current study.
• The subject anticipates a move outside the geographic area.

Where it is running

• Site Reference ID/Investigator# 8315 — Lafayette, California, United States
• Site Reference ID/Investigator# 8306 — Jacksonville, Florida, United States
• Site Reference ID/Investigator# 8308 — Orlando, Florida, United States
• Site Reference ID/Investigator# 8314 — Overland Park, Kansas, United States
• Site Reference ID/Investigator# 8307 — Farmington Hills, Michigan, United States
• Site Reference ID/Investigator# 8318 — Troy, Michigan, United States
• Site Reference ID/Investigator# 8309 — Eugene, Oregon, United States
• Site Reference ID/Investigator# 8316 — Portland, Oregon, United States
• Site Reference ID/Investigator# 8310 — Memphis, Tennessee, United States
• Site Reference ID/Investigator# 8319 — Virginia Beach, Virginia, United States
• Site Reference ID/Investigator# 8305 — Bellevue, Washington, United States
• Site Reference ID/Investigator# 8320 — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.